ArticleCell death & disease2025
TRIM59 suppresses mitochondrial-associated apoptosis to facilitate progression in papillary renal cell carcinoma via the ACAT1-cardiolipin pathway.
Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- TRIM59 Drives Bladder Cancer Progression Through E3 Ligase-Dependent K48-Linked Degradation of PTRF.Cancer science · 2026Article
- Regulatory networks of non-coding RNAs in renal cell carcinogenesis and therapeutic intervention strategies.World journal of urology · 2026Review
- The TRIM14-KIF1B Axis Drives Renal Injury in Diabetic Nephropathy Through TLR4/NF-κB Pathway Modulation.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- TRIM59 promotes immune evasion and tumor progression in lung adenocarcinoma via ubiquitin- proteasomal degradation of IRF3.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Papillary renal cell carcinoma (pRCC) is a challenging renal cell carcinoma subtype with poor prognosis and limited treatment options due to the lack of reliable biomarkers. The tripartite motif (TRIM) protein family is involved in various cellular processes, including oncogenesis. Among these, TRIM59 has emerged as a potential oncogene in multiple cancers; however, its role in pRCC progression remains unclear. Here, by using RNA sequencing data from The Cancer Genome Atlas (TCGA) and LASSO Cox regression analysis, we developed a prognostic model based on TRIM family genes for pRCC, with RiskScore demonstrating potential as a prognostic biomarker. Through the comparison of overall survival (OS) and progression-free survival (PFS), we identified TRIM59 as the primary research target. TRIM59 was markedly overexpressed in pRCC tissues, and correlated with poor OS. Functional studies showed that TRIM59 knockdown inhibited pRCC cell proliferation and induced mitochondrial-related apoptosis both in vitro and in vivo. Mechanistically, TRIM59 facilitated K27- and K63-linked ubiquitination and degradation of Acetyl-CoA Acetyltransferase 1 (ACAT1) at lysine 174 (K174), a critical enzyme in mitochondrial lipid metabolism. This disruption of lipid homeostasis in clear cell renal carcinoma (pRCC), particularly in mitochondrial cardiolipin metabolism, inhibited mitochondria-dependent apoptosis and, consequently, enhanced tumorigenesis. These findings suggest TRIM59 as a biomarker and potential therapeutic target, supporting precision oncology strategies for pRCC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.